• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors

    7/19/22 4:26:27 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care
    Get the next $SGHT alert in real time by email

    MENLO PARK, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced the appointment of Tamara Fountain, M.D. to its Board of Directors, effective July 15, 2022. As part of her duties, Dr. Fountain has joined Sight Sciences' Nominating and Corporate Governance Committee.

    "Tamara is an accomplished ophthalmologist with both incredible clinical and academic credentials as well as significant ophthalmic leadership experience. She will provide Sight Sciences and our Board of Directors with new and valuable perspectives as we continue to scale our businesses in glaucoma and ocular surface disease," said Paul Badawi, co-founder and Chief Executive Officer of Sight Sciences. "I'm confident in Tamara's ability to provide clarity and focus in our efforts to elevate the standard of care that is rooted in delivering clinical results that patients, surgeons, and payors expect from our innovative technologies and products. Her experience as a recognized leader in organized ophthalmology, including her past service as President of the American Academy of Ophthalmology (AAO) and her current service as a member of the Board of Directors of the American Board of Ophthalmology, will help us to strengthen our partnerships with the ophthalmic community and the patients we serve."

    Dr. Fountain served as the President of AAO in 2021, was named to the board of directors of the American Board of Ophthalmology in January 2022 and is a former President of the Illinois Society of Eye Physicians and Surgeons, serving from January 2002 to December 2005. Currently, Dr. Fountain is a surgeon in a multi-specialty practice, Ophthalmology Partners, Ltd. located in Deerfield and Lake Bluff, Illinois. In addition to her clinical practice, Dr. Fountain is a Professor of Ophthalmology at Rush University Medical Center and Section Chair Emeritus of its department of Oculoplastic and Reconstructive Surgery. Dr. Fountain received her undergraduate degree from Stanford University and Medical Degree from Harvard Medical School. She completed her residency at Johns Hopkins University Hospital's Wilmer Eye Institute and a fellowship in ophthalmic plastic and reconstructive surgery at the University of Southern California's Doheny Eye Institute.

    "I am pleased to join Sight Sciences' Board of Directors and to be part of a company whose focus on elevating the standard of care for patients is driving sustained growth and creating value across the ophthalmic community.  Sight's innovation is centered around what's best for the patient and ophthalmic providers and I look forward to being part of a culture where the importance of improving patient outcomes in a cost-effective way is the foundation of their values," said Dr. Fountain.

    About Sight Sciences

    Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world's leading cause of irreversible blindness. The Company's TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by an eye care professional to address the leading cause of dry eye disease. For more information, visit www.sightsciences.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

    Investor contact:

    Philip Taylor

    Gilmartin Group

    415.937.5406

    [email protected]

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e8b0bb04-8c69-42df-abad-5af8fbd81c66



    Primary Logo

    Get the next $SGHT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGHT

    DatePrice TargetRatingAnalyst
    12/6/2024$5.50Buy
    UBS
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    8/21/2024$10.00Buy
    Lake Street
    9/12/2023$10.00 → $4.50Neutral → Underperform
    BofA Securities
    9/12/2023$15.00 → $5.50Overweight → Neutral
    Piper Sandler
    9/12/2023Outperform → Mkt Perform
    William Blair
    8/24/2023$12.00 → $8.40Overweight → Equal-Weight
    Morgan Stanley
    7/10/2023$15.00 → $9.00Buy → Neutral
    Citigroup
    More analyst ratings

    $SGHT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Encrantz Staffan bought $381,958 worth of shares (90,525 units at $4.22) and was granted 30,952 shares, increasing direct ownership by 10% to 1,377,964 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      6/6/25 9:10:58 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Director Encrantz Staffan bought $376,429 worth of shares (98,782 units at $3.81), increasing direct ownership by 9% to 1,256,487 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      6/3/25 9:57:16 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/29/25 9:31:17 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mazzacco Catherine was granted 30,952 shares, increasing direct ownership by 65% to 78,507 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      6/10/25 9:32:33 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Director Larsen-Becker Brenda Jane was granted 30,952 shares, increasing direct ownership by 64% to 79,040 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      6/9/25 9:54:50 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Director Rogers Erica J. was granted 30,952 shares, increasing direct ownership by 21% to 175,352 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      6/9/25 9:54:33 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care